Oncology Episode Payment Model in Hawaii

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03523546

Enrollment

Registered

2018-05-14

Start date

2018-08-01

Completion date

2028-01-31

Last updated

2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colon Cancer, Lung Cancer

Brief summary

The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.

Detailed description

The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.

Interventions

OTHERCancer Episode Payment Model (CEM)

Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Any oncologist who practices with Hawaii Oncology and is a participating provider.

Exclusion criteria

* Any provider who does not practice with Hawaii Oncology.

Design outcomes

Primary

Measure	Time frame	Description
Composite quality score	1 year	Quality metrics included in the oncology model will be compared across the two arms.
Episode cost	6 months	Total spending of oncology patients in the episode will be compared across the two arms.
Utilization of acute and specialty care	6 months	Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms

Secondary

Measure	Time frame	Description
Quality of care at end of life	6 months	Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms
Survival	one year	All cause mortality will be compared across the two arms

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026